SOLICITATION NOTICE
Q -- Evaluate mtDNA copy number in peripheral blood lymphocytes
- Notice Date
- 8/2/2012
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120157-MD
- Archive Date
- 8/31/2012
- Point of Contact
- Miguel Diaz, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
miguel.diaz@nih.gov, cr214i@nih.gov
(miguel.diaz@nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6079, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG) plans to procure on a sole source basis with the Changhua Christian Hospital of No. 480, Zhōngzhèng Road, Lugang Township ChanghuaCounty, Taiwan 505 to evaluate mtDNA copy number in peripheral blood lymphocytes. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 621511 and the business size standard is $13.5 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined that there is no opportunity to acquire Green Products or Services under this contract. The period of performance shall be twelve (12) months from date of award. Mitochondria supply cells with energy by synthesizing ATP through the process of oxidative phosphorylation, and also play a critical role in apoptosis. Mitochondria contain their own genome, mitochondrial DNA (mtDNA), which consists of a 16.6kb double-stranded DNA molecule. The number of copies of mtDNA varies widely by cell type, and may be determined by both genetic and environmental characteristics. Mitochondrial DNA is also thought to be particularly vulnerable to mutations due to the lack of protective histones and the chromatin structure, inefficient DNA repair mechanisms, and potential exposure to reactive oxygen species generated in the process of oxidative phosphorylation; the mutation rate in mtDNA is 10 times higher than that of nuclear DNA. In recent years there has been increasing interest in the relationship between non-normal mtDNA copy number and cancer risk. Three small retrospective studies have observed higher levels of mitochondrial DNA content among prostate cases compared to controls; however, no studies have assessed the association prospectively. Elevated levels of mitochondrial DNA content among prostate cancer patients have also been associated with PSA recurrence and reduced survival. The purpose is to evaluate mtDNA copy number in peripheral blood lymphocytes and is association with prostate cancer risk. There are several methods to evaluate mitochondrial copy number, but not all methods are equally reliable or sensitive. We plan to utilize fluorescence-based quantitative polymerase chain reaction (QPCR) to determine mitochondrial copy number by estimating the threshold cycle number of the mitochondrial gene, ND1, and that of the nuclear β-globin gene, HBB. This method has been shown to be reliable and give reproducible results. The Liu laboratory in the Vascular and Genomic Research Center at Changhua Christian Hospital in Taiwan is currently collaborating with NCI investigators on several other related investigations of mtDNA copy number and cancer risk using this method. For scientific comparability, it is important that the assays and results be performed at the same laboratory for these ongoing DCEG projects. Additionally, the proposed contractor is the first lab in the world to develop this particular assay method for measuring mtDNA copy number. Changhua Chiristian Hospital is the only known source that can fulfill the requirements of this procurement. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 16, 2012. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Miguel Diaz, Contract Specialist at miguel.diaz@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120157-MD on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120157-MD/listing.html)
- Record
- SN02824250-W 20120804/120802235738-5363ccbc933a3ede5e731b688d680138 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |